Novel Protein Inhibitor Shows Antitumor Activity in Patients with NHL
Vall d'Hebron Institute of Oncology
Monotherapy with new PRMT5 inhibitor well tolerated with low toxicity in adults with B cell non-Hodgkin lymphomas
Fighting relapsed/refractory lymphoma during pregnancy requires critical decision-making from patients and providers